X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1443) 1443
Publication (159) 159
Book Review (24) 24
Book Chapter (7) 7
Magazine Article (7) 7
Conference Proceeding (4) 4
Book / eBook (3) 3
Reference (3) 3
Dissertation (1) 1
Paper (1) 1
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
male (860) 860
humans (831) 831
animals (778) 778
index medicus (777) 777
nootropic agents - therapeutic use (609) 609
nootropic agents - pharmacology (601) 601
neurosciences (539) 539
female (477) 477
pharmacology & pharmacy (450) 450
rats (397) 397
alzheimer's disease (314) 314
aged (297) 297
alzheimers-disease (287) 287
alzheimer disease - drug therapy (281) 281
memory (254) 254
nootropic agents - administration & dosage (252) 252
cognition - drug effects (221) 221
brain (220) 220
middle aged (220) 220
mice (215) 215
dementia (205) 205
psychiatry (205) 205
clinical neurology (204) 204
disease models, animal (203) 203
brain - drug effects (196) 196
adult (184) 184
cognition (177) 177
treatment outcome (172) 172
double-blind method (164) 164
memory - drug effects (164) 164
dose-response relationship, drug (163) 163
rats, wistar (156) 156
nootropic agents - adverse effects (153) 153
analysis (149) 149
rats, sprague-dawley (142) 142
double-blind (141) 141
maze learning - drug effects (141) 141
aged, 80 and over (138) 138
neurology (136) 136
donepezil (132) 132
cognition disorders - drug therapy (126) 126
neuropsychological tests (125) 125
nootropic agents - pharmacokinetics (122) 122
brain - metabolism (117) 117
piperidines - therapeutic use (112) 112
indans - therapeutic use (110) 110
oxidative stress (109) 109
time factors (107) 107
hippocampus - drug effects (103) 103
hippocampus (97) 97
neurons - drug effects (96) 96
article (95) 95
neuroprotective agents - pharmacology (95) 95
research (85) 85
cognitive ability (84) 84
cholinesterase inhibitors - therapeutic use (83) 83
memory disorders - drug therapy (83) 83
drug therapy (79) 79
behavioral sciences (78) 78
geriatrics & gerontology (75) 75
rat (74) 74
avoidance learning - drug effects (73) 73
long-term potentiation (72) 72
alzheimers disease (71) 71
behavior, animal - drug effects (71) 71
health aspects (71) 71
alzheimer disease - psychology (70) 70
neurons - metabolism (70) 70
nootropic agents - chemistry (70) 70
aging (69) 69
biochemistry & molecular biology (68) 68
neuroprotective agents - therapeutic use (68) 68
nootropic agents - blood (68) 68
clinical trials (67) 67
random allocation (66) 66
acetylcholine (63) 63
chemistry, medicinal (63) 63
motor activity - drug effects (63) 63
neurons (63) 63
young adult (63) 63
biomedicine (62) 62
mice, inbred c57bl (62) 62
neuroprotection (62) 62
brain - pathology (61) 61
care and treatment (61) 61
drugs (61) 61
alzheimer disease - metabolism (60) 60
hippocampus - metabolism (60) 60
acetylcholinesterase (59) 59
placebo-controlled trial (58) 58
nootropics (57) 57
stroke (57) 57
citicoline (56) 56
cognition - physiology (56) 56
impairment (56) 56
administration, oral (55) 55
cognition disorders - etiology (55) 55
efficacy (55) 55
performance (55) 55
schizophrenia (55) 55
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1395) 1395
Russian (47) 47
Hungarian (6) 6
Japanese (4) 4
German (3) 3
Chinese (2) 2
French (1) 1
Polish (1) 1
Spanish (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


AAPS Journal, ISSN 1550-7416, 04/2013, Volume 15, Issue 2, pp. 324 - 336
The therapeutic effects of curcumin in treating Alzheimer's disease (AD) depend on the ability to penetrate the blood-brain barrier. The latest nanoparticle... 
nanocurcumin | pharmacokinetic | Alzheimer's disease | oral route | behavior tests | PERMEABILITY | MEMORY DEFICITS | AMYLOID-BETA PROTEIN | FORMULATION | MICROPARTICLES | CELLULAR UPTAKE | BIOAVAILABILITY | MOUSE MODEL | A-BETA | CHEMOPREVENTIVE AGENT | PHARMACOLOGY & PHARMACY | Memory - drug effects | Curcumin - chemistry | Male | Polyethylene Glycols - chemistry | Curcumin - administration & dosage | Alzheimer Disease - pathology | Brain - metabolism | Nanoparticles | Plaque, Amyloid | Madin Darby Canine Kidney Cells | Behavior, Animal - drug effects | Female | Alzheimer Disease - psychology | Lactates - chemistry | Disease Models, Animal | Administration, Oral | Conditioning (Psychology) - drug effects | Drug Stability | Nootropic Agents - pharmacokinetics | Curcumin - pharmacokinetics | Alzheimer Disease - drug therapy | Mice, Transgenic | Technology, Pharmaceutical - methods | Nootropic Agents - blood | Permeability | Maze Learning - drug effects | Nootropic Agents - chemistry | Chemistry, Pharmaceutical | Blood-Brain Barrier - metabolism | Brain - drug effects | Particle Size | Fear | Povidone - chemistry | Animals | beta-Cyclodextrins - chemistry | Nootropic Agents - administration & dosage | Dogs | Brain - pathology | Mice | Alzheimer Disease - genetics | Nanotechnology | Alzheimer Disease - blood | Brain | Powders | Analysis | Drugstores | Medical tests | Cyclodextrins | Biopolymers | Polyols | Block copolymers
Journal Article
British Journal of Nutrition, ISSN 0007-1145, 07/2014, Volume 112, Issue 2, pp. 203 - 213
Journal Article
Neuropharmacology, ISSN 0028-3908, 01/2013, Volume 64, pp. 215 - 223
Phosphodiesterase 10A (PDE10A) is a novel target for the treatment of schizophrenia that may address multiple symptomatic domains associated with this... 
Schizophrenia | Phosphodiesterase 10A | Striatum | Cognition | OBJECT RETRIEVAL | CYCLIC-NUCLEOTIDE PHOSPHODIESTERASES | IMMUNOHISTOCHEMICAL LOCALIZATION | STRIATUM-ENRICHED PHOSPHODIESTERASE | AMPA RECEPTOR | SYNAPTIC PLASTICITY | NEUROSCIENCES | PREFRONTAL CORTEX | MEMORY DYSFUNCTION | DOPAMINE-D-2 RECEPTOR OCCUPANCY | ANIMAL-MODELS | PHARMACOLOGY & PHARMACY | Pyrimidines - blood | Memory, Episodic | Male | Macaca mulatta | Cognition Disorders - prevention & control | Antipsychotic Agents - therapeutic use | Behavior, Animal - drug effects | Neurons - metabolism | Phosphorylation - drug effects | Pyridines - administration & dosage | Phosphodiesterase Inhibitors - pharmacokinetics | Rats | Random Allocation | Neurons - enzymology | Corpus Striatum - drug effects | Pyrimidines - pharmacokinetics | Phosphodiesterase Inhibitors - therapeutic use | Schizophrenia - metabolism | Rats, Wistar | Antipsychotic Agents - blood | Pyridines - pharmacokinetics | Molecular Targeted Therapy | Corpus Striatum - metabolism | Dose-Response Relationship, Drug | Protein Processing, Post-Translational - drug effects | Schizophrenia - physiopathology | Cognition Disorders - etiology | Neurons - drug effects | Corpus Striatum - enzymology | Pyridines - therapeutic use | Nerve Tissue Proteins - antagonists & inhibitors | Phosphoric Diester Hydrolases - metabolism | Schizophrenia - blood | Pyrimidines - administration & dosage | Nootropic Agents - pharmacokinetics | Nootropic Agents - therapeutic use | Antipsychotic Agents - pharmacokinetics | Nootropic Agents - blood | Phosphodiesterase Inhibitors - blood | Phosphoric Diester Hydrolases - chemistry | Antipsychotic Agents - administration & dosage | Nerve Tissue Proteins - metabolism | Phosphodiesterase Inhibitors - administration & dosage | Pyridines - blood | Animals | Nootropic Agents - administration & dosage | Pyrimidines - therapeutic use | Schizophrenia - drug therapy | Executive Function - drug effects | Enzymes | Plasma physics | Protein binding
Journal Article
British Journal of Nutrition, ISSN 0007-1145, 01/2015, Volume 113, Issue 2, pp. 350 - 365
Common pharmacological treatments of mood disorders aim to modulate serotonergic neurotransmission and enhance serotonin levels in the brain. Brain serotonin... 
Well-being | Serotonin | LumiVida | Tryptophan | Depression | Cognition | Emotion | FEMALE VOLUNTEERS | PLASMA TRYPTOPHAN | COGNITIVE PERFORMANCE | DEPRESSED-PATIENTS | HEALTHY-SUBJECTS | LumiVida (TM) | ALPHA-LACTALBUMIN INCREASES | NEUTRAL AMINO-ACIDS | VULNERABLE SUBJECTS | NUTRITION & DIETETICS | MOOD | Protein Hydrolysates - metabolism | Stress, Psychological - prevention & control | Nootropic Agents - metabolism | Humans | Middle Aged | Reaction Time | Antidepressive Agents - metabolism | Tryptophan - metabolism | Cognitive Dysfunction - prevention & control | Mental Fatigue - metabolism | Sleep Wake Disorders - metabolism | Depression - metabolism | Egg Proteins, Dietary - adverse effects | Psychiatric Status Rating Scales | Mental Fatigue - prevention & control | Tryptophan - blood | Stress, Psychological - metabolism | Egg Proteins, Dietary - therapeutic use | Female | Dietary Supplements - adverse effects | Beverages | Egg Proteins, Dietary - metabolism | Antidepressive Agents - blood | Serotonin Agents - therapeutic use | Protein Hydrolysates - therapeutic use | Double-Blind Method | Stress, Psychological - blood | Cognitive Dysfunction - metabolism | Nootropic Agents - therapeutic use | Cognitive Dysfunction - blood | Nootropic Agents - blood | Nootropic Agents - adverse effects | Protein Hydrolysates - adverse effects | Serotonin Agents - metabolism | Serotonin Agents - adverse effects | Antidepressive Agents - therapeutic use | Mental Fatigue - blood | Depression - prevention & control | Energy Metabolism | Sleep Wake Disorders - blood | Sleep Wake Disorders - prevention & control | Tryptophan - adverse effects | Aged | Serotonin Agents - blood | Antidepressive Agents - adverse effects | Tryptophan - therapeutic use | Cohort Studies | Depression - blood | Amino acids | Emotional disorders | Cognition & reasoning | Dietary supplements
Journal Article
Neuropharmacology, ISSN 0028-3908, 01/2013, Volume 64, pp. 114 - 123
Previous studies have demonstrated that cognitive function can be restored in mouse models of Alzheimer's disease (AD) following administration of sildenafil,... 
PDE5 | Tadalafil | Alzheimer's disease | Memory | Blood–brain barrier | Blood-brain barrier | CYCLIC-NUCLEOTIDE PHOSPHODIESTERASES | ALZHEIMERS-DISEASE | MEMORY DEFICITS | GLYCOGEN-SYNTHASE KINASE-3 | CGMP-BINDING | NEUROSCIENCES | INHIBITION | MESSENGER-RNA | NITRIC-OXIDE | GMP PATHWAY | OBJECT RECOGNITION | PHARMACOLOGY & PHARMACY | Gene Expression Regulation, Enzymologic - drug effects | Sulfones - therapeutic use | Species Specificity | Nootropic Agents - metabolism | Humans | Half-Life | Macaca fascicularis | Male | Carbolines - metabolism | Phosphodiesterase 5 Inhibitors - pharmacokinetics | Brain - metabolism | Sildenafil Citrate | Tissue Distribution | Cognition Disorders - prevention & control | Cognition Disorders - etiology | Phosphodiesterase 5 Inhibitors - metabolism | Female | Phosphodiesterase 5 Inhibitors - therapeutic use | Purines - therapeutic use | Carbolines - blood | Carbolines - therapeutic use | Cyclic Nucleotide Phosphodiesterases, Type 5 - metabolism | Disease Models, Animal | Phosphodiesterase 5 Inhibitors - blood | Mice, Inbred C57BL | Nootropic Agents - pharmacokinetics | Alzheimer Disease - drug therapy | Nootropic Agents - therapeutic use | Mice, Transgenic | Piperazines - therapeutic use | Nootropic Agents - blood | Blood-Brain Barrier - metabolism | Brain - drug effects | Animals | Alzheimer Disease - metabolism | Brain - pathology | Cyclic Nucleotide Phosphodiesterases, Type 5 - genetics | Mice | Carbolines - pharmacokinetics | Alzheimer Disease - genetics | Neurosciences | Messenger RNA | Analysis | Smart drugs and nutrients | Universities and colleges
Journal Article
Neuropharmacology, ISSN 0028-3908, 01/2013, Volume 64, pp. 81 - 96
Long-term memory formation is known to be critically dependent upon gene expression in the brain. As a consequence, pharmacological enhancement of the... 
Chromatin | Cognitive enhancer | CREB | Epigenetic | Acetylation | Histone deacetylases | LONG-TERM-MEMORY | RUBINSTEIN-TAYBI-SYNDROME | TRANSCRIPTIONAL COACTIVATOR CBP | ELEMENT-BINDING PROTEIN | BETA-CATENIN | SYNAPTIC PLASTICITY | NEUROSCIENCES | ACETYLTRANSFERASE ACTIVITY | NEURITE OUTGROWTH | SMALL-MOLECULE INHIBITORS | PHARMACOLOGY & PHARMACY | GENE-TRANSCRIPTION | Embryo, Mammalian - drug effects | Nootropic Agents - metabolism | Neuronal Plasticity - drug effects | Drug Discovery - methods | Male | Neurons - cytology | Biphenyl Compounds - metabolism | Histone Deacetylase Inhibitors - blood | Embryo, Mammalian - metabolism | Prosencephalon - drug effects | Histone Deacetylase Inhibitors - pharmacokinetics | Biphenyl Compounds - pharmacology | Hydrazines - blood | Biphenyl Compounds - blood | Neurons - metabolism | Prosencephalon - metabolism | Neurons - drug effects | Animals, Newborn | Recombinant Proteins - metabolism | Dendrites - drug effects | Dendrites - metabolism | Nerve Tissue Proteins - antagonists & inhibitors | Biphenyl Compounds - pharmacokinetics | Hydrazines - pharmacology | Recombinant Proteins - antagonists & inhibitors | Histone Deacetylases - genetics | Mice, Inbred C57BL | Nootropic Agents - pharmacokinetics | Cells, Cultured | Histone Deacetylases - chemistry | Hydrazines - pharmacokinetics | Histone Deacetylases - metabolism | Mice, Transgenic | Nootropic Agents - blood | Nerve Tissue Proteins - genetics | Hydrazines - metabolism | Nerve Tissue Proteins - metabolism | Acetylation - drug effects | Animals | Embryo, Mammalian - cytology | Prosencephalon - cytology | Genes, Reporter - drug effects | Histone Deacetylase Inhibitors - pharmacology | Mice | Histones - metabolism | Histone Deacetylase Inhibitors - metabolism | Nootropic Agents - pharmacology | Genetic transcription | Cognition disorders | Neurons | Genes | Smart drugs and nutrients | acetylation | histone deacetylases | chromatin | epigenetic
Journal Article
Neuropharmacology, ISSN 0028-3908, 04/2017, Volume 116, pp. 247 - 259
Phosphodiesterases (PDEs), which hydrolyze and inactivate 3′, 5′-cyclic adenosine monophosphate (cAMP) and 3′, 5′-cyclic guanosine monophosphate (cGMP), play... 
Senescence-accelerated mouse (SAM) | 18F-FDG PET | Cilostazol | CREB phosphorylation | BBB | Memory | F-FDG PET | CHRONIC CEREBRAL HYPOPERFUSION | OXIDATIVE STRESS | AGE-RELATED DISRUPTIONS | ALZHEIMERS-DISEASE | CONTEXTUAL FEAR | COGNITIVE IMPAIRMENT | NEUROSCIENCES | SELECTIVE PHOSPHODIESTERASE INHIBITORS | F-18-FDG PET | MURINE MODEL | MITOCHONDRIAL DYSFUNCTION | PHARMACOLOGY & PHARMACY | INCREASED PERMEABILITY | Capillary Permeability - physiology | Amygdala - drug effects | Tetrazoles - pharmacology | Aging - drug effects | Capillary Permeability - drug effects | Fear - drug effects | Memory Disorders - metabolism | Male | Fear - physiology | Tetrazoles - blood | Blood-Brain Barrier - diagnostic imaging | Dentate Gyrus - drug effects | Time Factors | Phosphorylation - drug effects | Zonula Occludens-1 Protein - metabolism | Cyclic AMP - metabolism | Dentate Gyrus - diagnostic imaging | Memory Disorders - pathology | Disease Models, Animal | Tight Junctions - drug effects | Tight Junctions - metabolism | Amygdala - diagnostic imaging | Dentate Gyrus - metabolism | Conditioning, Classical - drug effects | Nootropic Agents - pharmacokinetics | Amygdala - metabolism | Aging - psychology | Nootropic Agents - blood | Blood-Brain Barrier - drug effects | Conditioning, Classical - physiology | Amygdala - pathology | Aging - pathology | Blood-Brain Barrier - metabolism | Blood-Brain Barrier - pathology | Animals | Memory Disorders - drug therapy | Memory Disorders - etiology | Cyclic AMP Response Element-Binding Protein - metabolism | Glucose - metabolism | Dentate Gyrus - pathology | Nootropic Agents - pharmacology | Tetrazoles - pharmacokinetics | Aging - metabolism | Proteins | Brain | Gerontology | Neurosciences | Cyclic adenylic acid | Drug discovery | Glucose | Adenylic acid | Cyclic guanylic acid | Dextrose | Protein binding | Pets | Analysis
Journal Article
Journal Article
Neuropharmacology, ISSN 0028-3908, 11/2016, Volume 110, Issue Pt A, pp. 419 - 430
Survivors of exposure to an organophosphorus nerve agent may develop a number of complications including long-term cognitive deficits (Miyaki et al., 2005;... 
Organophosphate | Epilepsy | Electroencephalography | Seizure | Anxiety | EP2 receptor | Novel object recognition | Open field | Status epilepticus | Light-dark box preference test | Hippocampus | DFP | PATHOPHYSIOLOGICAL ALTERATIONS | NERVOUS-SYSTEM | INDUCED BRAIN-DAMAGE | BASOLATERAL AMYGDALA | NEURONAL INJURY | SOMAN-INDUCED NEUROPATHOLOGY | NEUROSCIENCES | INTOXICATION | SUBWAY SARIN ATTACK | PHARMACOLOGY & PHARMACY | EXPOSURE | Status Epilepticus - psychology | Receptors, Prostaglandin E, EP2 Subtype - metabolism | Memory Disorders - metabolism | Status Epilepticus - drug therapy | Male | Anxiety - drug therapy | Recognition (Psychology) - physiology | Exploratory Behavior - physiology | Receptors, Prostaglandin E, EP2 Subtype - antagonists & inhibitors | Exploratory Behavior - drug effects | Discrimination (Psychology) - drug effects | Status Epilepticus - complications | Indoles - pharmacology | Anxiety - metabolism | Disease Models, Animal | Brain - physiopathology | Nootropic Agents - pharmacokinetics | Indoles - blood | Nootropic Agents - blood | Random Allocation | Rats, Sprague-Dawley | Brain - drug effects | Memory Disorders - prevention & control | Animals | Memory Disorders - etiology | Recognition (Psychology) - drug effects | Discrimination (Psychology) - physiology | Indoles - pharmacokinetics | Isoflurophate | Status Epilepticus - metabolism | Nootropic Agents - pharmacology | Prevention | Nerve gas | Medical colleges | Prostaglandins E | Seizures (Medicine) | Health aspects | epilepsy | organophosphate | status epilepticus | electroencephalography | anxiety | open field | seizure | hippocampus | light-dark box preference test | novel object recognition
Journal Article